Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport.

High-density lipoprotein (HDL) has been proposed to have several antiatherosclerotic properties, including the ability to mediate macrophage cholesterol efflux, antioxidant capacity, antiinflammatory properties, nitric oxide–promoting activity, and ability to transport proteins with their own intrinsic biological activities.1 HDL particles are critical acceptors of cholesterol from lipid-laden macrophages and thereby participate in the maintenance of net cholesterol balance in the arterial wall and in the reduction of proinflammatory responses by arterial cholesterol-loaded macrophages. The pathways that regulate HDL-mediated macrophage cholesterol efflux and disposition of cholesterol involve cell membrane–bound transporters, plasma lipid acceptors, plasma proteins and enzymes, and hepatic cellular receptors (Figure 1). From the earliest proposed concept for HDL-mediated cholesterol efflux,2,3 the concentration of the cholesterol content in HDL particles has been considered a surrogate measurement for the efficiency of the “reverse cholesterol transport” (RCT) process; however, macrophage-derived cholesterol represents a minor component of the cholesterol transported by HDL particles.4–7 One important pathway for cholesterol-mediated efflux from macrophage foam cells involves interaction between the ATP-binding cassette transporter A1 (ABCA1) and cholesterol-deficient and phospholipid-depleted apolipoprotein (apo) A-I complexes (pre-β migrating HDL or very small HDL [HDL-VS]; Figure 2).1,8 Subsequently, the ATP-binding cassette transporter G1 (ABCG1) mediates macrophage cholesterol efflux through interactions (Figure 3) with spherical, cholesterol-containing α-HDL particles (small HDL [HDL-S], medium HDL [HDL-M], large HDL [HDL-L], and very large (HDL-VL).1 In contrast, the scavenger receptor class B type I (SR-BI) is a multifunctional receptor that mediates bidirectional lipid transport in the macrophage, which is dependent on the content of cholesterol in lipid-laden macrophages. A more established role for SR-BI in cholesterol trafficking involves selective uptake of cholesteryl esters from mature HDL by the liver. Recent studies suggest that polymorphisms in SR-BI contribute to the functional capacity of this cholesterol …

[1]  M. Hayden,et al.  Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. , 2005, The Journal of clinical investigation.

[2]  M. Hayden,et al.  Alterations of plasma lipids in mice via adenoviral-mediated hepatic overexpression of human ABCA1 Published, JLR Papers in Press, May 1, 2003. DOI 10.1194/jlr.M300110-JLR200 , 2003, Journal of Lipid Research.

[3]  T. Sand,et al.  Raising High-Density Lipoprotein in Humans Through Inhibition of Cholesteryl Ester Transfer Protein: An Initial Multidose Study of Torcetrapib , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[4]  D. Rader,et al.  Lipases and HDL metabolism , 2002, Trends in Endocrinology & Metabolism.

[5]  P. Fitzgerald,et al.  A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. , 2010, Journal of the American College of Cardiology.

[6]  A. Tall,et al.  Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. , 2007, The Journal of clinical investigation.

[7]  L. Curtiss,et al.  Apolipoprotein A-I structural organization in high density lipoproteins isolated from human plasma , 2010, Nature Structural &Molecular Biology.

[8]  S. Yokoyama,et al.  Regulation of Cellular Cholesterol Efflux by Lecithin:Cholesterol Acyltransferase Reaction through Nonspecific Lipid Exchange (*) , 1996, The Journal of Biological Chemistry.

[9]  M. Krieger Charting the fate of the "good cholesterol": identification and characterization of the high-density lipoprotein receptor SR-BI. , 1999, Annual review of biochemistry.

[10]  Nadine H. Elowe,et al.  Biochemical characterization of cholesteryl ester transfer protein inhibitors , 2010, Journal of Lipid Research.

[11]  A. Tall,et al.  Cholesterol Efflux Potential and Antiinflammatory Properties of High-Density Lipoprotein After Treatment With Niacin or Anacetrapib , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[12]  D. Steinberg,et al.  Dissociation of tissue uptake of cholesterol ester from that of apoprotein A-I of rat plasma high density lipoprotein: selective delivery of cholesterol ester to liver, adrenal, and gonad. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. Tall,et al.  Scavenger Receptor Class B Type I as a Mediator of Cellular Cholesterol Efflux to Lipoproteins and Phospholipid Acceptors* , 1998, The Journal of Biological Chemistry.

[14]  D. Sviridov,et al.  Dynamics of reverse cholesterol transport: protection against atherosclerosis. , 2002, Atherosclerosis.

[15]  Helen H. Hobbs,et al.  Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor , 1996, Science.

[16]  D. Rader,et al.  Impact of Combined Deficiency of Hepatic Lipase and Endothelial Lipase on the Metabolism of Both High-Density Lipoproteins and Apolipoprotein B–Containing Lipoproteins , 2010, Circulation research.

[17]  D. Rader,et al.  The Ability to Promote Efflux Via ABCA1 Determines the Capacity of Serum Specimens With Similar High-Density Lipoprotein Cholesterol to Remove Cholesterol From Macrophages , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[18]  A. Tall,et al.  SR-BI inhibits ABCG1-stimulated net cholesterol efflux from cells to plasma HDL Published, JLR Papers in Press, October 24, 2007. , 2008, Journal of Lipid Research.

[19]  A. Tall,et al.  HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. , 2008, Cell metabolism.

[20]  M. Reilly,et al.  Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. , 2005, The Journal of clinical investigation.

[21]  P. Barter,et al.  Formation and Metabolism of Prebeta-Migrating, Lipid-Poor Apolipoprotein A-I , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[22]  T. Egashira,et al.  Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive. , 2000, Journal of lipid research.

[23]  Z. Fayad,et al.  Imaging of atherosclerosis. , 2011, Annual review of medicine.

[24]  A. Tall,et al.  Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. , 2000, The Journal of biological chemistry.

[25]  H. Mabuchi,et al.  Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol. , 1994, The Journal of clinical investigation.

[26]  Albert K Groen,et al.  Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. , 2006, The Journal of clinical investigation.

[27]  A. Tall,et al.  Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. , 1999, The Journal of clinical investigation.

[28]  K. Wakitani,et al.  A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits , 2000, Nature.

[29]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[30]  D. Rader,et al.  Dose-Dependent Acceleration of High-Density Lipoprotein Catabolism by Endothelial Lipase , 2003, Circulation.

[31]  Yong Ji,et al.  Scavenger Receptor BI Promotes High Density Lipoprotein-mediated Cellular Cholesterol Efflux* , 1997, The Journal of Biological Chemistry.

[32]  T. V. van Berkel,et al.  Dual role for scavenger receptor class B, type I on bone marrow-derived cells in atherosclerotic lesion development. , 2004, The American journal of pathology.

[33]  D. Sviridov,et al.  5A Apolipoprotein Mimetic Peptide Promotes Cholesterol Efflux and Reduces Atherosclerosis in Mice , 2010, Journal of Pharmacology and Experimental Therapeutics.

[34]  E. Podrez,et al.  Scavenger receptor BI modulates platelet reactivity and thrombosis in dyslipidemia. , 2010, Blood.

[35]  A. Tall,et al.  The implications of the structure of the bactericidal/permeability-increasing protein on the lipid-transfer function of the cholesteryl ester transfer protein. , 1998, Current opinion in structural biology.

[36]  D. Rader,et al.  A novel endothelial-derived lipase that modulates HDL metabolism , 1999, Nature Genetics.

[37]  R. F. Hoyt,et al.  Hepatic lipase expression in macrophages contributes to atherosclerosis in apoE-deficient and LCAT-transgenic mice. , 2003, The Journal of clinical investigation.

[38]  J. Glomset,et al.  SOME PROPERTIES OF A CHOLESTEROL ESTERIFYING ENZYME IN HUMAN PLASMA. , 1964, Biochimica et biophysica acta.

[39]  Ji-Young Lee,et al.  Minimal Lipidation of Pre-β HDL by ABCA1 Results in Reduced Ability to Interact with ABCA1 , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[40]  G. Dernick,et al.  Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport[S] , 2010, Journal of Lipid Research.

[41]  R. S. Meidell,et al.  Effect of Up-regulating Individual Steps in the Reverse Cholesterol Transport Pathway on Reverse Cholesterol Transport in Normolipidemic Mice* , 2001, The Journal of Biological Chemistry.

[42]  P. Giral,et al.  Stimulation of Cholesterol Efflux by LXR Agonists in Cholesterol-Loaded Human Macrophages Is ABCA1-Dependent but ABCG1-Independent , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[43]  V. Fuster,et al.  The BioImage Study: novel approaches to risk assessment in the primary prevention of atherosclerotic cardiovascular disease--study design and objectives. , 2010, American heart journal.

[44]  P. Eacho,et al.  Phospholipid Transfer Protein Is Regulated by Liver X Receptors in Vivo * , 2002, The Journal of Biological Chemistry.

[45]  Colin Berry,et al.  Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. , 2007, JAMA.

[46]  D. Rader,et al.  Effects of Cholesteryl Ester Transfer Protein Inhibition on High-Density Lipoprotein Subspecies, Apolipoprotein A-I Metabolism, and Fecal Sterol Excretion , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[47]  A. Tall,et al.  ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Jianwen Fang,et al.  Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes , 2008, Proceedings of the National Academy of Sciences.

[49]  H. Brewer,et al.  Cellular localization and trafficking of the human ABCA1 transporter. , 2001 .

[50]  M. Nakano,et al.  Effects of sphingomyelin on apolipoprotein E- and lipoprotein lipase-mediated cell uptake of lipid particles. , 2003, Biochimica et biophysica acta.

[51]  Farhad Rezaee,et al.  Proteomic analysis of high‐density lipoprotein , 2006, Proteomics.

[52]  K. Moore,et al.  Deletion of ABCA1 and ABCG1 Impairs Macrophage Migration Because of Increased Rac1 Signaling , 2011, Circulation research.

[53]  A. Tall,et al.  Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. , 1990, The New England journal of medicine.

[54]  J. Pais de Barros,et al.  Worsening of Diet-Induced Atherosclerosis in a New Model of Transgenic Rabbit Expressing the Human Plasma Phospholipid Transfer Protein , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[55]  P. Connelly,et al.  The role of hepatic lipase in lipoprotein metabolism. , 1999, Clinica chimica acta; international journal of clinical chemistry.

[56]  E. Fisher,et al.  Phospholipid Transfer Protein Deficiency Impairs Apolipoprotein-B Secretion from Hepatocytes by Stimulating a Proteolytic Pathway through a Relative Deficiency of Vitamin E and an Increase in Intracellular Oxidants* , 2005, Journal of Biological Chemistry.

[57]  Paul T. Tarr,et al.  Characterization of the Human ABCG1 Gene , 2001, The Journal of Biological Chemistry.

[58]  D. Rader,et al.  The roles of different pathways in the release of cholesterol from macrophages Published, JLR Papers in Press, August 29, 2007. , 2007, Journal of Lipid Research.

[59]  W. J. Johnson,et al.  Effects of Acceptor Particle Size on the Efflux of Cellular Free Cholesterol (*) , 1995, The Journal of Biological Chemistry.

[60]  H. Brewer,et al.  ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. , 2001, The Journal of clinical investigation.

[61]  Agnes Pasquet,et al.  Imaging the vulnerable plaque. , 2011, Journal of the American College of Cardiology.

[62]  F. Grosveld,et al.  Elevation of systemic PLTP, but not macrophage-PLTP, impairs macrophage reverse cholesterol transport in transgenic mice. , 2009, Atherosclerosis.

[63]  B. Lamarche,et al.  Evidence that hepatic lipase deficiency in humans is not associated with proatherogenic changes in HDL composition and metabolism Published, JLR Papers in Press, June 1, 2004. DOI 10.1194/jlr.M400090-JLR200 , 2004, Journal of Lipid Research.

[64]  R. F. Hoyt,et al.  Adenoviral expression of human lecithin-cholesterol acyltransferase in nonhuman primates leads to an antiatherogenic lipoprotein phenotype by increasing high-density lipoprotein and lowering low-density lipoprotein. , 2009, Metabolism: clinical and experimental.

[65]  Takeshi Kimura,et al.  MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo , 2010, Proceedings of the National Academy of Sciences.

[66]  Subramaniam Pennathur,et al.  Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. , 2007, The Journal of clinical investigation.

[67]  A. Jonas,et al.  Sphingomyelin Inhibits the Lecithin-Cholesterol Acyltransferase Reaction with Reconstituted High Density Lipoproteins by Decreasing Enzyme Binding* , 1996, The Journal of Biological Chemistry.

[68]  Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels. , 2001 .

[69]  R. Shamburek,et al.  Lecithin Cholesterol Acyltransferase: An Anti- or Pro-atherogenic Factor? , 2011, Current atherosclerosis reports.

[70]  Perttu S. Niemelä,et al.  Structure of spheroidal HDL particles revealed by combined atomistic and coarse-grained simulations. , 2008, Biophysical journal.

[71]  D. Rader,et al.  Increased Atherosclerosis in Mice Lacking Apolipoprotein A-I Attributable to Both Impaired Reverse Cholesterol Transport and Increased Inflammation , 2005, Circulation research.

[72]  M. Phillips,et al.  Characterization of nascent HDL particles and microparticles formed by ABCA1-mediated efflux of cellular lipids to apoA-I Published, JLR Papers in Press, January 17, 2006. , 2006, Journal of Lipid Research.

[73]  P. Lesnik,et al.  Cholesteryl Ester Transfer Protein Expression Partially Attenuates the Adverse Effects of SR-BI Receptor Deficiency on Cholesterol Metabolism and Atherosclerosis* , 2011, The Journal of Biological Chemistry.

[74]  R. Brasseur,et al.  Apolipoprotein L-I is the trypanosome lytic factor of human serum , 2003, Nature.

[75]  J. Parks,et al.  Lecithin:Cholesterol Acyltransferase Deficiency Increases Atherosclerosis in the Low Density Lipoprotein Receptor and Apolipoprotein E Knockout Mice* , 2002, The Journal of Biological Chemistry.

[76]  G. Franceschini,et al.  Functional Lecithin: Cholesterol Acyltransferase Is Not Required for Efficient Atheroprotection in Humans , 2009, Circulation.

[77]  D. Mangelsdorf,et al.  An oxysterol signalling pathway mediated by the nuclear receptor LXRα , 1996, Nature.

[78]  M. Reilly,et al.  Endothelial Lipase Concentrations Are Increased in Metabolic Syndrome and Associated with Coronary Atherosclerosis , 2005, PLoS medicine.

[79]  Charles C Schwartz,et al.  Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans Published, JLR Papers in Press, May 16, 2004. DOI 10.1194/jlr.M300511-JLR200 , 2004, Journal of Lipid Research.

[80]  Tanya M. Teslovich,et al.  Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids , 2010, Nature.

[81]  A. Waring,et al.  Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I , 2008 .

[82]  D. Rader,et al.  Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[83]  P. Barter,et al.  Impact of Short-Term Administration of High-Density Lipoproteins and Atorvastatin on Atherosclerosis in Rabbits , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[84]  Per Leanderson,et al.  Lipoproteomics II: Mapping of proteins in high‐density lipoprotein using two‐dimensional gel electrophoresis and mass spectrometry , 2005, Proteomics.

[85]  Ahmed Tawakol,et al.  Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial , 2011, The Lancet.

[86]  K. Moore,et al.  Selective uptake of HDL cholesteryl esters and cholesterol efflux from mouse peritoneal macrophages independent of SR-BI Published, JLR Papers in Press, August 22, 2006. , 2006, Journal of Lipid Research.

[87]  T. V. van Berkel,et al.  Scavenger receptor B1 (SR-B1) substrates inhibit the selective uptake of high-density-lipoprotein cholesteryl esters by rat parenchymal liver cells. , 1997, The Biochemical journal.

[88]  R. Mahley,et al.  Putting cholesterol in its place: apoE and reverse cholesterol transport. , 2006, The Journal of clinical investigation.

[89]  G. Anantharamaiah,et al.  D-4F, an Apolipoprotein A-I Mimetic Peptide, Inhibits the Inflammatory Response Induced by Influenza A Infection of Human Type II Pneumocytes , 2004, Circulation.

[90]  J. Albers,et al.  Different phospholipid transfer protein complexes contribute to the variation in plasma PLTP specific activity. , 2011, Biochimica et biophysica acta.

[91]  John A Wagner,et al.  Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies , 2007, The Lancet.

[92]  H. Jansen Hepatic lipase: Friend or foe and under what circumstances? , 2004, Current atherosclerosis reports.

[93]  A. Kontush,et al.  Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis , 2006, Pharmacological Reviews.

[94]  M. Jauhiainen,et al.  Quantitation of the active and low-active forms of human plasma phospholipid transfer protein by ELISA Published, JLR Papers in Press, November 16, 2003. DOI 10.1194/jlr.D300023-JLR200 , 2004, Journal of Lipid Research.

[95]  J. Danesh,et al.  Major lipids, apolipoproteins, and risk of vascular disease. , 2009, JAMA.

[96]  Robert L Wilensky,et al.  Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. , 2011, The New England journal of medicine.

[97]  E. Tuzcu,et al.  Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis: Insights From ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation) , 2008, Circulation.

[98]  A. Vaughan,et al.  Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol efflux* , 2009, Journal of Lipid Research.

[99]  R. Krauss,et al.  HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. , 2011, Clinical chemistry.

[100]  Paul Schoenhagen,et al.  Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. , 2003, JAMA.

[101]  Scott D Covey,et al.  Scavenger Receptor Class B Type I–Mediated Protection Against Atherosclerosis in LDL Receptor–Negative Mice Involves Its Expression in Bone Marrow–Derived Cells , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[102]  H. Saito,et al.  Mechanism of ATP-binding Cassette Transporter A1-mediated Cellular Lipid Efflux to Apolipoprotein A-I and Formation of High Density Lipoprotein Particles* , 2007, Journal of Biological Chemistry.

[103]  J. Heinecke,et al.  Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein. , 2010, Chemical research in toxicology.

[104]  D. Rader,et al.  The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis This work was supported by P01-HL22633 from the NHLBI. Published, JLR Papers in Press, December 8, 2008. , 2009, Journal of Lipid Research.

[105]  M. Phillips,et al.  High-density lipoprotein heterogeneity and function in reverse cholesterol transport , 2010, Current opinion in lipidology.

[106]  A. Tall,et al.  The failure of torcetrapib: was it the molecule or the mechanism? , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[107]  M. Jauhiainen,et al.  Cholesterol efflux from macrophage foam cells is enhanced by active phospholipid transfer protein through generation of two types of acceptor particles. , 2007, Biochemistry.

[108]  D. Mangelsdorf,et al.  LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[109]  M. Eriksson,et al.  Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. , 1999, Circulation.

[110]  W. J. Johnson,et al.  Mechanisms and consequences of cellular cholesterol exchange and transfer. , 1987, Biochimica et biophysica acta.

[111]  A. Jonas Lecithin-cholesterol acyltransferase in the metabolism of high-density lipoproteins. , 1991, Biochimica et biophysica acta.

[112]  M. Heller,et al.  Mass spectrometry‐based analytical tools for the molecular protein characterization of human plasma lipoproteins , 2005, Proteomics.

[113]  A. Vaughan,et al.  ABCG1 Redistributes Cell Cholesterol to Domains Removable by High Density Lipoprotein but Not by Lipid-depleted Apolipoproteins* , 2005, Journal of Biological Chemistry.

[114]  J. Glomset,et al.  The plasma lecithins:cholesterol acyltransferase reaction. , 1968, Journal of lipid research.

[115]  A. Kontush,et al.  Small, Dense HDL Particles Exert Potent Protection of Atherogenic LDL Against Oxidative Stress , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[116]  S. Goldstein,et al.  A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. , 1981, Journal of lipid research.

[117]  T. Shioda,et al.  MicroRNA-33 and the SREBP Host Genes Cooperate to Control Cholesterol Homeostasis , 2010, Science.

[118]  Jan Albert Kuivenhoven,et al.  Genetic variant of the scavenger receptor BI in humans. , 2011, The New England journal of medicine.

[119]  Aaron N. Chang,et al.  Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. , 2011, The Journal of clinical investigation.

[120]  A. Tall,et al.  Increased Inflammatory Gene Expression in ABC Transporter–Deficient Macrophages: Free Cholesterol Accumulation, Increased Signaling via Toll-Like Receptors, and Neutrophil Infiltration of Atherosclerotic Lesions , 2008, Circulation.

[121]  P. Alaupovic The concept of apolipoprotein-defined lipoprotein families and its clinical significance , 2003, Current atherosclerosis reports.

[122]  A. Zwinderman,et al.  Compromised LCAT Function Is Associated With Increased Atherosclerosis , 2005, Circulation.

[123]  H. Brewer,et al.  Overexpression of human lecithin:cholesterol acyltransferase in cholesterol-fed rabbits: LDL metabolism and HDL metabolism are affected in a gene dose-dependent manner. , 1997, Journal of lipid research.

[124]  N. Weissman,et al.  The year in intracoronary imaging. , 2010, JACC. Cardiovascular imaging.

[125]  A. Kontush,et al.  Proteomic Analysis of Defined HDL Subpopulations Reveals Particle-Specific Protein Clusters: Relevance to Antioxidative Function , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[126]  Daniel S. Ory,et al.  miR-33 links SREBP-2 induction to repression of sterol transporters , 2010, Proceedings of the National Academy of Sciences.

[127]  F. Karpe,et al.  Lipoprotein metabolism in hepatic lipase deficiency: studies on the turnover of apolipoprotein B and on the effect of hepatic lipase on high density lipoprotein. , 1988, Journal of lipid research.

[128]  R. Hegele,et al.  Hepatic lipase deficiency. Clinical, biochemical, and molecular genetic characteristics. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[129]  H. Brewer,et al.  LCAT modulates atherogenic plasma lipoproteins and the extent of atherosclerosis only in the presence of normal LDL receptors in transgenic rabbits. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[130]  W. Annema,et al.  Role of Hepatic Lipase and Endothelial Lipase in High-Density Lipoprotein—Mediated Reverse Cholesterol Transport , 2011, Current atherosclerosis reports.

[131]  J. Albers,et al.  Active plasma phospholipid transfer protein is associated with apoA-I- but not apoE-containing lipoproteins Published, JLR Papers in Press, March 6, 2006. , 2006, Journal of Lipid Research.

[132]  A. Tall,et al.  Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins , 1989, Nature.

[133]  K. Moore,et al.  MiR-33 Contributes to the Regulation of Cholesterol Homeostasis , 2010, Science.

[134]  D. Rader,et al.  Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. , 2003, The Journal of clinical investigation.

[135]  C. Fielding,et al.  A protein cofactor of lecithin:cholesterol acyltransferase. , 1972, Biochemical and biophysical research communications.

[136]  A. Zwinderman,et al.  Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans: A Randomized Phase II Dose-Response Study , 2002, Circulation.

[137]  D. Rader,et al.  Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. , 2007, The Journal of clinical investigation.

[138]  A. Vaughan,et al.  Phospholipid Transfer Protein Interacts with and Stabilizes ATP-binding Cassette Transporter A1 and Enhances Cholesterol Efflux from Cells* , 2003, Journal of Biological Chemistry.

[139]  R. F. Hoyt,et al.  Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[140]  M. Liu,et al.  Role of sphingomyelin in the regulation of cholesterol esterification in the plasma lipoproteins. Inhibition of lecithin-cholesterol acyltransferase reaction. , 1993, The Journal of biological chemistry.

[141]  J. Brady,et al.  Analysis of Glomerulosclerosis and Atherosclerosis in Lecithin Cholesterol Acyltransferase-deficient Mice* , 2001, The Journal of Biological Chemistry.

[142]  M. Reilly,et al.  Overexpression of Apolipoprotein A-I Promotes Reverse Transport of Cholesterol From Macrophages to Feces In Vivo , 2003, Circulation.

[143]  A. Tall,et al.  HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. , 2006, The Journal of clinical investigation.

[144]  F. Grosveld,et al.  Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. , 2000, Arteriosclerosis, thrombosis, and vascular biology.